The intravenous injection of a suspension of ellagic acid increased pulmonary metastases from 33 per-cent in the controls to 85 per-cent in the ellagic acid (EA) treated rats. A significant shortening of the silicone and glass clotting times, and a reduction in bleeding following the partial amputation of the tail was also observed after the infusion of EA. There was no obvious untoward side effect of EA in any of the animals studied in these series.
Get full access to this article
View all access options for this article.
References
1.
AgostinoD., GrossiC. E., and ClifftonE. E.: Effect of human fibrinolysin on the incidence of hepatic metastases in simulated colon carcinoma in rats.Ann. Surg., 153: 388–394, 1961.
2.
AgostinoD., and ClifftonE. E.: Anticoagulant and the development of pulmonary metastases: Anticoagulant effect on the Walker 256 carcinosarcoma in the rat.Arch. Surg., 84: 87–91, 1962.
3.
AgostinoD., and ClifftonE. E.: Decrease in pulmonary metastases: Potentiation of nitrogen mustard by heparin and fibrinolysin.Ann. Surg., 157: 400–408, 1963.
4.
AgostinoD., and ClifftonE. E.: The control of bleeding in splenectomized animals by ellagic acid.Thromb. Diath. Haem., 18: 797–800, 1967.
5.
AgostinoD., and ClifftonE. E.: The effect of ellagic acid on traumatic bleeding in Warfarin treated rats.Path. Europ., 2: 421–426, 1967.
6.
AgostinoD., and ClifftonE. E.: The growth and transplantability of the carcinosarcoma of Walker 256 in the ascitic form.Experientia, 24: 166–167, 1968.
7.
AgostinoD., and ClifftonE. E.: Control of bleeding in splenectomized and Coumadin treated animals: Potentiation of ellagic acid by Vitamin K.Nagoya. Med. J., 14: 65–73, 1968.
8.
AlkjaersigN., FletcherA. P., and SherryS.: E-amino-caproic acid: Activation of plasminogen activation.J. Biol. Chem., 234: 832–837, 1959.
9.
BaleW. F., SparL. L., CoodlandR. E., and IzzoM. J.: Inhibition of fibrinolysis in rat tumor by epsilon-amino-caproic acid.Fed. Proc., 20: 58, 1961.
10.
BottiR. E., and RatnoffO. D.: Studies on the pathogenesis of thrombosis: Experimental hypercoagulable state induced by intravenous injection of ellagic acid.J. lab. clin. Med., 64: 385–398, 1964.
11.
ClifftonE. E., and AgostinoD.: Effect of inhibitors of fibrinolytic enzymes on development of pulmonary metastases.J. nat. Cancer Inst., 33: 753–763, 1964.
12.
ClifftonE. E., AgostinoD., and MindeK.: The effect of hyperlipemia on pulmonary metastases of Walker 256 in rats.Cancer Res., 21: 1062–1067, 1963.
13.
ClifftonE. E., GirolamiA., and AgostinoD.: The effect of Ellagic Acid on thrombin induced hemorrhagic syndrome in rats.Blood, 28: 253–257, 1966.
14.
ClifftonE. E.: The effect of ellagic acid on the coagulation mechanism and on traumatic bleeding.Amer. J. med. Sci., 254: 117–123, 1967.
15.
ComanD. R., EisembergR. B., and McCutcheonM.: Factors affecting the distribution of tumor metastases. Experiment with the V2 carcinoma in rabbits.Cancer Res., 9: 649–651, 1949.
16.
FisherB., and FisherE. R.: Experimental studies of factors which influence hepatic metastases. VII. Effect of anticoagulants.Surgery, 50: 240–246, 1961.
17.
GirolamiA., AgostinoD., and ClifftonE. E.: The effect of ellagic acid on coagulation in vivo.Blood, 27: 93–102, 1966.
18.
GirolamiA., and ClifftonE. E.: Hypercoagulable state induced in humans by the intravenous administration of purified ellagic acid.Thromb. Diath. Haem., 17: 165–172, 1967.
19.
GrossiC. E., AgostinoD., and ClifftonE. E.: The effect of human fibrinolysin on pulmonary metastases of the Walker 256 carcinosarcoma.Cancer Res., 20: 604–608, 1960.
20.
IatridisP. G., and FergursonJ. H.: Experimental thrombosis in rabbits: Evidence that alkaline phosphatase enhances the thrombogenic effect of the injected ellagic acid.Thromb. Diath. Haem., 16: 645–656, 1966.
21.
KrautH., and Koerbel-EnkhardtR.: Das Verhalten des Kallikrein-Inaktivators eus Rinderparotis gegenuber Proteolytischen Fermenten.Leistungen und Ergebnisse der Neuzeitichen Chirurgie Stuttgart, p. 62, 1958.
22.
LawrenceE. A., BrownD. E., MooreD. P., and BernsteinG. I.: A thromboplastic property of neoplasms.Surg. Forum, 4: 968–971, 1953.
23.
LibermanJ. S., BorreroJ., UsdenetaE., and WrightJ. S.: Thrombophlebitis and cancer.JAMA, 177: 542, 1961.
24.
McKayD. G., BerghousG. M., and CruseV.: Activation of Hageman factor by ellagic acid and the generalized Schwartzman reaction.Amer. J. Path., 54: 393–420, 1969.
25.
MikataA., ImaiL., and O'NeilR. M.: Effect of lipemia on implantation of rabbit carcinoma.Exp. Mol. Path., 1: 37–43, 1962.
26.
MootzeG., AgostinoD., and ClifftonE. E.: Alterations of fibrinogen, plasminogen and inhibitors of plasmin with growth of the V2 carcinoma in rabbits.J. nat. Cancer Inst., 35: 567–572, 1965.
27.
O'MearaR. A. Q.: Coagulative properties of cancer.Irish. J. med. Sci., 6: 474–479, 1958.
28.
ThornesR. D.: Fibrinogen and the interstitial behavior of cancer. In: Endogenous factors influencing host tumor balance., p. 255–266. University of Chicago Press, 1967.
29.
RatnoffO. D., and RosenblumJ. M.: Role of Hageman factor on inhibition of clotting by glass: Evidence that glass frees Hageman factor from inhibition.Amer. J. Med., 25: 160–168, 1958.
30.
RatnoffO. D., DavieE. W., and MallettD. L.: Studies on the activation of Hageman factor. Evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent.J. clin. Invest., 40: 803–808, 1961.
31.
RatnoffO. D., and CrumJ. D.: Activation of Hageman factor by solutions of ellagic acid.J. lab. clin. Med., 63: 359–377, 1964.
32.
WoodS.Jr.: Experimental studies of the intravascular dissemination of ascites V2 carcinoma cells in rabbits with special reference to fibrinogen and fibrinolytic agents.Bull. Swiss Acad. Sci., 20: 92–121, 1964.
